Compare Gold Fields Limited (GFI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Moderna, Inc. — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.5× Gold Fields Limited's market cap, and Gold Fields Limited pays a 6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Moderna, Inc. for 59 Days on average.
| GFI | MRNA | |
|---|---|---|
Market Cap | $31.87B | $78.65B |
Volume | 4,169,651 | 37,373,437 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $203.46 |
52-Week Low | $31.25 | $22.36 |
Typical Hold Time | 49 Days | 59 Days |
Enterprise Value | $32.47B | $74.80B |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.
The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
